Beijing Luzhu receives Chinese approval for recombinant RSV vaccine trials
Beijing Luzhu Biotechnology said China has approved clinical trials for its recombinant vaccine against respiratory syncytial virus, or RSV.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
According to Newsmetry API, Beijing Luzhu Biotechnology Co Ltd said its recombinant RSV vaccine has been approved for clinical trials in China.
why it matters
The decision moves the vaccine program into clinical testing and represents a regulatory milestone for Beijing Luzhu Biotechnology.
sources
- Beijing Luzhu Biotechnology Says Recombinant RSV Vaccine Approved For Clinical Trials In China — Newsmetry API, 12 October 2026 at 15:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗